the below from a US patent application for therapeutic annexin V. It's out of Martin Herrmann's team, PS & autoimmunity giants, (who have recently started a company called Responsif in Germany, hoping to develop this tech). This is an excellent read to understand the role of PS in normal cell turnover, cancer, viral and parasitic infections, as well as the implications (now proven in the clinic by Peregrine's mab) of blocking PS.
long time ago post... but interesting, that this patent by Martin Herrmann expired
-----------
Original:
Inventors
Wolf Maximilian Bertling, Martin Herrmann, Joachim Robert Kalden, Reinhard Voll, Der Mark Klaus Von, Otmar Zoller,
Phosphatidylserine is a global immunosuppressive signal in efferocytosis, infectious disease, and cancer Open
R B Birge1,10, S Boeltz2,10, S Kumar1,10, J Carlson3,10, J Wanderley4,10, D Calianese1,10, M Barcinski5,10, R A Brekken6,7,10, X Huang6,7,10, J T Hutchins3,10, B Freimark3,10, C Empig3,10, J Mercer8,10, A J Schroit9,10, G Schett2,10 and M Herrmann2,10
1Department of Microbiology, Biochemistry and Molecular Genetics, Cancer Center, Rutgers New Jersey Medical School, 205 South Orange Ave, Newark, NJ 07103, USA
2Department of Internal Medicine 3—Rheumatology and Immunology, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), University Hospital Erlangen, 91054 Erlangen, Germany
3Peregrine Pharmaceuticals, 14282 Franklin Avenue, Tustin, CA 92780, USA
4Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil
5Laboratório de Biologia Celular, Instituto Oswaldo Cruz, Rio de Janeiro, Brazil
6Division of Surgical Oncology, Department of Surgery, Hamon Center for Therapeutic Oncology Research, Dallas, TX 75390-8593, USA
7Department of Pharmacology, University of Texas Southwestern Medical Center, Dallas, TX 75390-8593, USA
8Medical Research Council Laboratory for Molecular Cell Biology, University College London, Gower Street, London WC1E 6BT, UK
9Simmons Cancer Center and the Department of Immunology, University of Texas Southwestern Medical Center, Dallas, TX 75390 USA
10These authors contributed equally to this work.
The large amount of evidence obtained with AnxA5 and PS-targeting antibodies supports the notion that PS is a fundamental immune checkpoint akin to or upstream of the CTLA4 and PD-1/PD-L1 checkpoints. Late-stage clinical trials evaluating the PS-targeting antibody, bavituximab, are in progress in multiple oncology indications, while agents targeting PS receptors are in various stages of pre-clinical and clinical development.
.. .. Conflict of interest
JC, JTH, BF, and CE are paid employees of Peregrine Pharmaceuticals. RAB receives funding from and is a consultant for Peregrine Pharmaceuticals. MH wants to disclose the involvement in Patent Application EP1356818 A3 filed at the European Patent Office in 1995 and entitled ‘Drug, in particular for modulating the immunological response for the control of viruses, tumors, bacteria, and parasites’. This patent application has already expired. Peregrine Pharmaceuticals, Inc., is the owner or exclusive licensee of hundreds of unexpired worldwide patents broadly covering compositions that target PS and various methods of use, including to treat cancer and viral infections. The remaining authors declare no conflict of interests.
More interesting... is that Herrmann based out of Germany and then I think Troy Luster (ex-Peregrine on patents..etc) and how Evotec and Broad Institute making a deal. I hope everyone is after the golden biomarkers to solidify that PS Targeting is the #1 ingredient.
--------------------------------
Evotec AG. (7/6/16). "Press Release: Evotec Enters License Agreement for Access to CRISPR-Cas9 Gene Editing Technology". Hamburg.
Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) announced today that the Company has entered into a non-exclusive licence agreement with the Broad Institute of MIT and Harvard for the use of CRISPR-Cas9 gene editing technology.
Under the terms of this research tool licence, Evotec gains access to IP related to CRISPR-Cas9 and will apply the technology to its drug discovery offerings and R&D activities, especially for the development of research tools and in target identification, and to further strengthen its post phenotypical screening target deconvolution platform.
With this agreement, Evotec obtains non-exclusive access to the leading technology on the market for gene editing.
Dr Mario Polywka, Chief Operating Officer of Evotec, commented: "Alongside Evotec's comprehensive stem cell capabilities, the ability to offer CRISPR-Cas9 research tools emphasises the Company's continuing approach to establishing cutting-edge technologies for the benefit of our partners and growing R&D pipeline."
ABOUT THE CRISPR-CAS9 SYSTEM
CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) is a naturally-occurring bacterial immune system. Researchers have harnessed this system as a genome editing tool for mammalian cells. The CRISPR-Cas9 gene editing system allows researchers to target specific genes, to mutate these and achieve knock out or enhance the expression of these in living cells. Through application of the CRISPR-Cas9 technology, valuable insights into the functions of these genes in disease establishment and progression can be gained.
"Bavituximab is a first-in-class phosphatidylserine (PS)-targeting monoclonal antibody that is the cornerstone of a broad clinical pipeline." -- Big Pharmas nightmare... unless they are fortunate enough to have The Bavi Edge!
